Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.
Adenovirus gene therapy for intraperitoneal (IP) cancer is limited in clinical trials by inefficient tumor cell transduction and development of peritoneal adhesions. We have shown previously that normal virus tropism can be ablated by physically shielding the virus surface with reactive hydrophilic...
Autores principales: | Morrison, J, Briggs, S, Green, N, Fisher, K, Subr, V, Ulbrich, K, Kehoe, S, Seymour, L |
---|---|
Formato: | Journal article |
Lenguaje: | English |
Publicado: |
2008
|
Ejemplares similares
-
Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
por: Morrison, J, et al.
Publicado: (2009) -
Retargeting adenovirus gene therapy via the epidermal growth factor receptor
por: Morrison, J, et al.
Publicado: (2006) -
Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
por: Green, N, et al.
Publicado: (2008) -
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
por: Fisher, K, et al.
Publicado: (2001) -
E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells.
por: Bachtarzi, H, et al.
Publicado: (2011)